Ajooni Biotech Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Fri Mar 20 2026

Ajooni Biotech Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Ajooni Biotech was listed on the National Stock Exchange (NSE) on 07-May-2021. Ajooni Biotech share has its face value of 2 per share, and its NSE symbol is AJOONI. The company operates in the Healthcare sector and primarily belongs to the Biotechnology industry.

Table of Contents

Ajooni Biotech Q4 Results 2026 Preview

Ajooni Biotech Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-14% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 12-16% YoY.
EBITDA to rise 11-15%.
Ajooni Biotech is expected to show Moderate Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Ajooni Biotech Share Performance

Over the past six months, Ajooni Biotech share price has Up by 22% to 4.4.
Moreover, over the past year, the stock has Up by 37%
Despite this weak short-term performance, Ajooni Biotech stock has delivered a financially sound 175% return over the past 5 years.
As of today, 20-03-2026, the Ajooni Biotech share price is trading at 4.4 per share.

Key Factors to Watch for Ajooni Biotech Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Biotechnology industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Ajooni Biotech

Ajooni Biotech specializes in manufacturing cattle feed and feed supplements, catering primarily to livestock farmers and dairy businesses. The company focuses on providing quality animal nutrition products, aiming to improve livestock health and productivity in the agricultural sector.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Ajooni Biotech is gear up to announce its Q4 FY26 results. Analysts expect 11-14% revenue growth, a 12-16% rise in PAT, and a 11-15% rise in EBITDA. Ajooni Biotech focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Ajooni Biotech Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.